Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer
Science Advances · 2023
DOI: 10.1126/sciadv.adk1098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2023. Verfasst von Sujin Hyung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Research Institute, Samsung Medical Center, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Exosomes, MicroRNAs. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Gastric cancer (GC) with peritoneal metastases and malignant ascites continues to have poor prognosis. Exosomes mediate intercellular communication during cancer progression and promote therapeutic resistance. Here, we report the significance of exosomes derived from malignant ascites (EXO Ascites ) in cancer progression and use modified exosomes as resources for cancer therapy. EXO Ascites from patients with GC stimulated invasiveness and angiogenesis in an ex vivo three-dimensional autologous tumor spheroid microfluidic system. EXO Ascites concentration increased invasiveness, and blockade of their secretion suppressed tumor progression. In MET -amplified GC, EXO Ascites contain abundant MET; their selective delivery to tumor cells enhanced angiogenesis and invasiveness. Exosomal MET depletion substantially reduced invasiveness; an additive therapeutic effect was induced when combined with MET and/or VEGFR2 inhibition in a patient-derived MET -amplified GC model. Allogeneic MET-harboring exosome delivery induced invasion and angiogenesis in a MET non-amplified GC model. MET -amplified patient tissues showed higher exosome concentration than their adjacent normal tissues. Manipulating exosome content and production may be a promising complementary strategy against GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Precision Medicine Research Institute, Samsung Medical Center, Seoul, Republic of Korea.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of BioNano Technology, Gachon University, Gyeonggi 13120, Republic of Korea.
- Neocella Inc., Irvine, CA 92606, USA.
- Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
ORCID-Profile: Sujin Hyung, Jihoon Ko, You Jeong Heo, Steven M Blum, Seung Tae Kim, Joon Oh Park, Won Ki Kang, Samuel J Klempner, Jeeyun Lee
Zitieren
APA
Hyung, S., Ko, J., Heo, Y. J., Blum, S. M., Kim, S. T., Park, S. H., Park, J. O., Kang, W. K., Lim, H. Y., Klempner, S. J., & Lee, J. (2023). Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer. Science Advances. https://doi.org/10.1126/sciadv.adk1098
Vancouver
Hyung S, Ko J, Heo YJ, Blum SM, Kim ST, Park SH, et al. Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer. Science Advances. 2023. doi:10.1126/sciadv.adk1098
BibTeX
@article{Hyung2023,
author = {Hyung, Sujin and Ko, Jihoon and Heo, You Jeong and Blum, Steven M and Kim, Seung Tae and Park, Se Hoon and Park, Joon Oh and Kang, Won Ki and Lim, Ho Yeong and Klempner, Samuel J and Lee, Jeeyun},
title = {Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer},
journal = {Science Advances},
year = {2023},
doi = {10.1126/sciadv.adk1098}
}
EUVIMED